NCCN Guidelines recognises Novartis’ ribociclib as Category 1 preferred breast cancer adjuvant treatment
- Posted on October 24, 2024
- By Financial Express
- 4 Views
NCCN Guidelines recognises Novartis’ ribociclib as Category 1 preferred breast cancer adjuvant treatment
In addition to the recent FDA approval of Kisqali for EBC patients in the US and CHMP positive opinion in Europe, regulatory reviews for Kisqali as an EBC treatment are ongoing worldwide.
